217 related articles for article (PubMed ID: 12734321)
21. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
22. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Vakaet L
J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
[No Abstract] [Full Text] [Related]
23. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K; Brown P
J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
[No Abstract] [Full Text] [Related]
24. Déjà vu for breast cancer two?
Stearns V; Davidson NE
J Natl Cancer Inst; 2004 Apr; 96(7):497-9. PubMed ID: 15069104
[No Abstract] [Full Text] [Related]
25. New insights into endocrine therapy for young women with breast cancer.
Di Lascio S; Pagani O
Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
[TBL] [Abstract][Full Text] [Related]
26. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
Giannessi PG
Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
[No Abstract] [Full Text] [Related]
27. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
28. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
29. Breast cancer highlights.
Kuter I
Oncologist; 1999; 4(4):299-308. PubMed ID: 10476541
[No Abstract] [Full Text] [Related]
30. [2nd European Breast Cancer Conference, Bruxelles, September 26-30, 2000. Interview with Anthony Howell].
Howell A
Tumori; 2000; 86(6):A1-4. PubMed ID: 11271673
[No Abstract] [Full Text] [Related]
31. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Atkins CD
J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
[No Abstract] [Full Text] [Related]
32. Ovarian ablation as a treatment for breast cancer.
Sainsbury R
Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
[TBL] [Abstract][Full Text] [Related]
33. New strategies for the treatment of breast cancer.
Bentrem DJ; O'Regan RM; Jordan VC
Breast Cancer; 2001; 8(4):265-74. PubMed ID: 11791116
[No Abstract] [Full Text] [Related]
34. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
36. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
37. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
39. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
40. San Antonio Breast Cancer Symposium explores DCIS "battleground".
Gottlieb N
J Natl Cancer Inst; 2000 Feb; 92(4):295-7. PubMed ID: 10675372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
